Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-Current Deffered Revenue (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $11.4 million as the latest value for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $11.4 million; the TTM value through Dec 2025 reached $11.4 million, changed N/A, while the annual FY2025 figure was $11.4 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue hit $11.4 million in Q4 2025 for Kymera Therapeutics, down from $14.0 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $64.7 million in Q1 2021 and bottomed at $3.2 million in Q2 2024.
  • Average Non-Current Deffered Revenue over 5 years is $27.6 million, with a median of $23.9 million recorded in 2022.
  • On a YoY basis, Non-Current Deffered Revenue climbed as much as 4.36% in 2024 and fell as far as 84.38% in 2024.
  • Kymera Therapeutics' Non-Current Deffered Revenue stood at $39.3 million in 2021, then decreased by 28.74% to $28.0 million in 2022, then tumbled by 40.11% to $16.8 million in 2023, then plummeted by 80.98% to $3.2 million in 2024, then soared by 258.73% to $11.4 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $11.4 million, $14.0 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2024 respectively.